🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China flag China · Delayed Price · Currency is CNY
8.02
-0.49 (-5.76%)
Nov 20, 2026, 3:04 PM CST

SHE:301060 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,2371,4471,7421,6684,1821,766
Other Revenue
0.760.760.256.7217.511.91
1,2381,4481,7421,6744,1991,778
Revenue Growth
-18.78%-16.88%4.05%-60.13%136.14%43.62%
Cost of Revenue
940.671,1051,4101,3452,4201,105
Gross Profit
297.28342.87332.53329.311,779672.9
Selling, General & Admin
250.94278.39304.25302.06539.66319.11
Research & Development
26.5741.0559.9748.86109.439.44
Other Operating Expenses
1.793.655.013.273.54.93
Operating Expenses
223.41327.98394.9484.87708.33378.75
Operating Income
73.8714.89-62.37-155.551,071294.15
Interest Expense
-4.13-6.41-10.81-8.17-8.46-3.27
Interest & Investment Income
15.912.5610.635.583.538.93
Currency Exchange Gain (Loss)
-0.19-0.19-1.02-0.57-0.560.02
Other Non Operating Income (Expenses)
3.740.571.520.99-0.05-0.21
EBT Excluding Unusual Items
89.1721.41-62.06-157.721,065299.62
Impairment of Goodwill
----9.97-12.45-
Gain (Loss) on Sale of Investments
0.770.05-13.06-2.121.663.93
Gain (Loss) on Sale of Assets
-1.14-1.275.671.93-0.36-0.03
Asset Writedown
-4.15-12.67-17.14-1.26-115.07-
Legal Settlements
-1.32-1.32-19.93-5.09--
Other Unusual Items
4.324.323.7120.99-34.7914.51
Pretax Income
87.6510.53-102.82-153.24904.44318.03
Income Tax Expense
36.6425.95-4.238.47165.3956.41
Earnings From Continuing Operations
51.02-15.42-98.59-161.71739.06261.62
Minority Interest in Earnings
-10.05-15.32-10.8520.12-121.73-57.78
Net Income
40.96-30.75-109.44-141.59617.32203.84
Net Income to Common
40.96-30.75-109.44-141.59617.32203.84
Net Income Growth
----202.85%84.68%
Shares Outstanding (Basic)
389384405405401352
Shares Outstanding (Diluted)
389384405405401352
Shares Change
-3.64%-5.18%0.19%1.00%13.63%0.02%
EPS (Basic)
0.11-0.08-0.27-0.351.540.58
EPS (Diluted)
0.11-0.08-0.27-0.351.540.58
EPS Growth
----166.52%84.64%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
293.02210.36139.7148.1-145.91104.63
Free Cash Flow Per Share
0.750.550.340.37-0.360.30
Dividend Per Share
0.1800.1800.200-0.3000.300
Dividend Growth
-10.00%-10.00%--0%-
Gross Margin
24.01%23.68%19.09%19.67%42.37%37.84%
Operating Margin
5.97%1.03%-3.58%-9.29%25.50%16.54%
Profit Margin
3.31%-2.12%-6.28%-8.46%14.70%11.46%
Free Cash Flow Margin
23.67%14.53%8.02%8.85%-3.48%5.88%
EBITDA
135.577.681.95-106.341,133338.96
EBITDA Margin
10.95%5.36%0.11%-6.35%26.98%19.06%
D&A For EBITDA
61.6362.7964.3349.2162.2144.82
EBIT
73.8714.89-62.37-155.551,071294.15
EBIT Margin
5.97%1.03%-3.58%-9.29%25.50%16.54%
Effective Tax Rate
41.80%246.44%--18.29%17.74%
Revenue as Reported
1,2381,4481,7421,6744,1991,778
Advertising Expenses
-0.620.790.93.23.39